Since 1995, Reliable Business Intelligence for Clinical Laboratories, Pathology Groups and Laboratory Diagnostics

Volume XXIII No. 6 - May 2, 2016

Theranos in the News, for Better and Worse

Commentary and Opinion by R. Lewis Dark / By R. Lewis Dark

IT’S BEEN AN EVENTFUL COUPLE OF MONTHS for Theranos, the lab testing company that says its goal is to disrupt the clinical laboratory industry. Novelists cannot write fiction as compelling as the unfolding real story about this controversial company.

During March and April, The Wall Street Journal published a series of articles that revealed the extent of the problems Theranos had with CLIA inspections of its clinical laboratory in Newark, California. The Journal published its analysis of the CLIA inspection report and the serious deficiencies identified during lab inspections that happened last fall and earlier this year.

To access this post, you must purchase The Dark Report.

At Executive War College 2016, Two Big Lab Market Trends

Clinical Laboratory Trends / By Robert Michel

CEO SUMMARY: What happens when 100 lab experts interact with an audience of more than 850 lab administrators, pathologists, and IVD executives from across the United States and seven other nations? A consensus of sorts emerges and during this 2016 edition of the Executive War College on Lab and Pathology Management, that consensus was how: …

At Executive War College 2016, Two Big Lab Market Trends Read More »

To access this post, you must purchase The Dark Report.

200-Analyte Medication Test Panel Adds Value for Physicians

Clinical Laboratory / By Joseph Burns

CEO SUMMARY: Delivering more value with lab tests requires going beyond simply working with physicians to improve test utilization by focusing on unnecessary or inappropriate tests. PeaceHealth Laboratories in Oregon successfully executed a two-step strategy to add value with its testing services. First, the lab combined a proprietary test with a new care protocol to …

200-Analyte Medication Test Panel Adds Value for Physicians Read More »

To access this post, you must purchase The Dark Report.

Gene Testing Lab Goes ‘Cold Turkey,’ Stops Billing Health Plans

Laboratory Billing / By Joseph Burns

CEO SUMMARY: Last year, Kailos Genetics stopped collecting third-party payment, dropped its prices sharply, and started marketing its genetic-screening tests directly to consumers and physicians. At the time, 100% of its revenue came from third-party payers. Today, it gets 100% of its revenue from consumers. After eliminating third-party payment, revenue dropped precipitously, but is now …

Gene Testing Lab Goes ‘Cold Turkey,’ Stops Billing Health Plans Read More »

To access this post, you must purchase The Dark Report.

May 2, 2016 Intelligence: Late Breaking Lab News

Late Breaking Lab News / By Robert Michel

Like the Sword of Damocles of Greek myth, market price reporting by labs under the Protecting Access to Medicare Act (PAMA) continues to hang over the heads of the nation’s clinical laboratories. However, instead of a threat, PAMA market price reporting may soon become a reality. News reports indicate that, as of April 21, the White …

May 2, 2016 Intelligence: Late Breaking Lab News Read More »

To access this post, you must purchase The Dark Report.

Attorney Cautions Laboratories Against Waiving Patient Fees

Laboratory Compliance / By Joseph Burns

WHEN A CLINICAL LAB WAIVES patients’ fees in exchange for lab test referrals, competing labs face a legal dilemma. If the competing lab does not match the offer, it could lose volume to this aggressive sales technique. But if the lab does match the offer, it could run afoul of health plan requirements not to …

Attorney Cautions Laboratories Against Waiving Patient Fees Read More »

To access this post, you must purchase The Dark Report.

Theranos Saga Just Keeps Getting More Intriguing

TDR Insider / By Mary Van Doren

IT’S BEEN AN EVENTFUL COUPLE OF MONTHS for Theranos, the lab testing company that says its goal is to disrupt the clinical laboratory industry. Novelists cannot write fiction as compelling as the unfolding real story about this controversial company.

During March and April, The Wall Street Journal published a series of articles that revealed the extent of the problems Theranos had with CLIA inspections of its clinical laboratory in Newark, California. The Journal published its analysis of the CLIA inspection report and the serious deficiencies identified during lab inspections that happened last fall and earlier this year.

To access this post, you must purchase The Dark Report.

;